Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01.Entry into a Material Definitive Agreement

On March 31, 2017, Interpace Diagnostics Group, Inc., a Delaware
corporation (the Company), entered into a waiver agreement (the
Waiver Agreement), with the holder (the Holder) of the Companys
Senior Secured Convertible Note (as described in the Original
8-K). to the Waiver Agreement, the Holder waived all rights to
Section 7(b) of the Senior Secured Convertible Note, including,
without limitation, any right to have an adjustment to the
Conversion Price (as defined in the Senior Secured Convertible
Note) of the Senior Secured Convertible Note or the right to
substitute the Variable Price (as defined in the Senior Secured
Convertible Note) for the Conversion Price of the Senior Secured
Convertible Note, unless and until the Company obtains
Stockholder Approval (as defined in the Senior Secured
Convertible Note).

The foregoing descriptions are qualified in their entirety by
reference to the full text of the agreements, which are filed as
exhibits to this Current Report on Form 8-K and incorporated
herein by reference in their entirety.

Through March 31, 2017, the Holder has converted $4,321,663 of
the Senior Secured Convertible Note into 1,730,534 shares of the
Companys common stock.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

* Filed herewith

Previously filed

About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) closed its last trading session down -0.32 at 2.63 with 1,067,356 shares trading hands.